Alnylam Pharmaceuticals and Collaborators at CNRS – Université de Montpellier Publish Paper on Novel Synthetic Method for Bi-functional 3p-siRNAs

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators from the Institut des Biomolécules Max Mousseron at CNRS – Université de Montpellier, France, have reported a new synthetic method for bi-functional 3p-siRNAs. 3p-siRNAs were first described by Alnylam scientists and collaborators (Poeck et al., Nature Medicine, 14: 1256-1263, 2008) and are designed to achieve both silencing of target genes and activation of desired immunostimulatory pathways. These new data on synthesis of 3p-siRNAs were published in the American Chemical Society’s journal, Organic Letters (DOI: 10.1021/ol1004214.)